| Assessment Status |
Rapid Review Complete |
| HTA ID |
22048 |
| Drug |
Melatonin |
| Brand |
Slenyto® |
| Indication |
For the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome (SMS), where sleep hygiene measures have been insufficient. |
| Rapid review commissioned |
05/07/2022 |
| Rapid review completed |
09/08/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of prolonged release melatonin (Slenyto®) compared with the current standard of care. |
